Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report)'s stock price reached a new 52-week low on Tuesday. The company traded as low as $10.26 and last traded at $10.3350, with a volume of 59,181 shares changing hands. The stock had previously closed at $10.49.
Analyst Upgrades and Downgrades
GENB has been the subject of several recent analyst reports. Weiss Ratings downgraded Generate Biomedicines from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday. HC Wainwright restated a "buy" rating on shares of Generate Biomedicines in a research note on Friday, October 30th. Finally, Wall Street Zen lowered Generate Biomedicines from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Generate Biomedicines currently has an average rating of "Moderate Buy" and an average target price of $26.40.
View Our Latest Research Report on GENB
Generate Biomedicines Trading Down 4.8%
The company's 50-day moving average price is $14.23 and its two-hundred day moving average price is $14.09. The company has a market cap of $1.28 billion and a P/E ratio of -6.21.
Generate Biomedicines (NASDAQ:GENB - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.18). The firm had revenue of $4.22 million for the quarter. As a group, analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in GENB. Aquatic Capital Management LLC bought a new position in Generate Biomedicines during the third quarter worth $904,000. Goldman Sachs Group Inc. bought a new position in shares of Generate Biomedicines in the 3rd quarter worth about $2,189,000. State Street Corp lifted its position in shares of Generate Biomedicines by 3.8% in the 3rd quarter. State Street Corp now owns 546,337 shares of the company's stock worth $8,206,000 after buying an additional 19,772 shares during the last quarter. Alps Advisors Inc. boosted its holdings in shares of Generate Biomedicines by 31.4% in the 3rd quarter. Alps Advisors Inc. now owns 170,042 shares of the company's stock valued at $2,554,000 after buying an additional 40,636 shares during the period. Finally, Summa Corp. acquired a new position in shares of Generate Biomedicines in the 3rd quarter valued at about $250,000.
Generate Biomedicines Company Profile
(
Get Free Report)
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Generate Biomedicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Generate Biomedicines wasn't on the list.
While Generate Biomedicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.